Affiliation:
1. Pain Management Center, Cincinnati Children's Hospital Cincinnati Ohio USA
Abstract
AbstractIntroductionAt a single‐center pediatric hospital, the neurokinin‐1 receptor antagonist aprepitant was used to treat refractory pruritus in epidermolysis bullosa (EB) and atopic dermatitis (AD).MethodsThirty‐seven patients were included (24 EB patients, 13 AD patients), ages 10 months to 37 years.Results58% (14/24) of patients with EB and 85% (11/13) of patients with AD reported aprepitant was effective in decreasing their pruritus, with age‐related differences in efficacy observed in EB patients, and access to the medication by insurance denial or availability of the drug as a barrier to use.ConclusionsAprepitant shows promise in controlling refractory pruritus in pediatric EB and AD patients and deserves further study.